{"name":"HanAll BioPharma Co., Ltd.","slug":"hanall-biopharma-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ATH-399A","genericName":"ATH-399A","slug":"ath-399a","indication":"Other","status":"phase_1"},{"name":"ATH-399A 10 mg","genericName":"ATH-399A 10 mg","slug":"ath-399a-10-mg","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"HL-040XC","genericName":"HL-040XC","slug":"hl-040xc","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"HL036 Ophthalmic Solution","genericName":"HL036 Ophthalmic Solution","slug":"hl036-ophthalmic-solution","indication":"Dry eye disease or ocular surface disease (specific indication not publicly disclosed)","status":"phase_3"}]}],"pipeline":[{"name":"ATH-399A","genericName":"ATH-399A","slug":"ath-399a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HL-040XC","genericName":"HL-040XC","slug":"hl-040xc","phase":"phase_3","mechanism":"HL-040XC is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"ATH-399A 10 mg","genericName":"ATH-399A 10 mg","slug":"ath-399a-10-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HL036 Ophthalmic Solution","genericName":"HL036 Ophthalmic Solution","slug":"hl036-ophthalmic-solution","phase":"phase_3","mechanism":"HL036 is an ophthalmic solution designed to treat ocular surface disease, likely through anti-inflammatory or lubricating mechanisms.","indications":["Dry eye disease or ocular surface disease (specific indication not publicly disclosed)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1zclJEc01ZUEVLM0NNcENtellEVE56NDBEaHVaS3ZLNERYRmVNbE9jdVFma01sbkVsQTZyT2Q4SEN4Qld4dklXSkc4Y0p6bWk3WjNsNWE0UHROaGt3cXR4VWluR3Q1bVd2dUZFbGJR0gFyQVVfeXFMUEozNk5LZ185a3dmRWU3NFQxMEtuNDRfNUYwampORzNtVFlSbjdORF9fSk56N25qdWJfdXFtZHV6dm1JeWlkaGwtWHJtNWR6Q2d2UmhVb3hvd05rb3FXVUFkWGpiV2o3SEZaZDhUUFg1b1B3?oc=5","date":"2026-01-22","type":"earnings","source":"koreabiomed.com","summary":"Hanall Biopharma posts record 2025 revenue on probiotic, hair loss drug sales - koreabiomed.com","headline":"Hanall Biopharma posts record 2025 revenue on probiotic, hair loss drug sales","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE4tWk43M0dxanNNaHNzdm04WHBrcTBROEVOOVMzaHFSc1l5SzVLWTR6bnlVN3RYbThzNmFfbWdLei1saDVLWndwRW01Q3FtTHZQRS1XLTVBUEhSQ05LR2U2N0JYSGxWb3pwWWRBaFRn?oc=5","date":"2025-12-02","type":"pipeline","source":"팜이데일리","summary":"Trust Dividend for HanAll, Valuation Penalty for Peptron·Caregen[K-Bio Pulse] - 팜이데일리","headline":"Trust Dividend for HanAll, Valuation Penalty for Peptron·Caregen[K-Bio Pulse] - 팜이데일리","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPVlo0UlJ3YmZfN1Foa3J1end3NHMyb0hXekVqQ0h3X2l6SVFwcnZlQkdGNXhqZzFGZWMwTUxxZkU5QTBZcUNGNDRheUIxWWVkMkZySm9qMXU0bnVadmVaMGRHdEF6RjU3SDJWM0VqNWQyaUJlUkNWY3puLUNIb1pSbk1HZEtBZFNkdmlkN1EzTmM4bjFkNkFpRHc0NjlZRnpWMDE1VGhkUzg?oc=5","date":"2025-06-17","type":"deal","source":"BioWorld News","summary":"Korea biotech roundup: four financings, six R&D deals mid-June - BioWorld News","headline":"Korea biotech roundup: four financings, six R&D deals mid-June","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1nTWxWUC0yVmVnLW93V25qUmd3SXNqbFVEeFk4MUdZTXhXa0dnUURrdjZDUU4tU2Qxa0VjTEsxU0tyTnZyRGhRTjhWWjV3T21sanRaalFXdUtEVHFGOHZ6TXJDd3lnVkh3dFRRUTZ30gFyQVVfeXFMTzRlZ3RVSFFHMnZuYnR5RDYwb2lxMW5LMjRRZE1fYU15eXVQNDczMXhjcndPS3puWGx3ZjRpZVBCRXJIMXVIb2xzTjhGMVdsMXpfWlhGaFc4QktlQkRtbUtINmtQUGZYOURhV2lITWhiR1lB?oc=5","date":"2025-03-05","type":"pipeline","source":"koreabiomed.com","summary":"HanAll Biopharma's batoclimab earns orphan drug designation in Japan for TED - koreabiomed.com","headline":"HanAll Biopharma's batoclimab earns orphan drug designation in Japan for TED","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AJBVV95cUxONWhOLU5qOUhpSV9kaFYtVW94VS1LNlluNXlxaFF0NXJES0xVVndtMWZLUzVpaldHSlJ6d3ppb1ZNOVlwYzZrWjdsVldYWEJYeXdieENCQk12Z1ppRF9tSDZRc0hzUFFjWC1oNTN5aWFXdS1lZktUUHJhVUpMWHY3YnM2UWxwT2U1eW5xMXBuWXBoSUxZVS1XMGxXcDBVZTVsbU1fdkczN2E0cDljOHBETXpfMDRUZkViVC1FbGM0dy1PbHhRc25FcWJUVzRCTzFtYnNQZm5EOXBUMDg2TGtBUlNidXdtUFNrLUZpcUF2S1dXV1Y2S2UtRFAyUVpCemdyb2V3RUxsZFNGMUJ2R1poMGhxd01Mek42d01kLTVEWkJIT0NrempzdXlYXzc2S1NYRTBmd0paZE9OZkdpY2Fzay1GOWVkTUJuaTdzQm5JVngtWDZRMG1qU01KMjk5T0ty?oc=5","date":"2024-11-25","type":"trial","source":"prnewswire.com","summary":"HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease - prnewswi","headline":"HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQZlRtVXJxSC1pSlZKQ1ozdHRsWkpuQWliQnMtRnJUSE9TX1ZwWkFhazNueURIM1NYUXBBSXNaejVFMDlJUVBzS2FYbGh2bVI0bFFhTUs0bndPUmFJMEJORjZIUFBMRURzMUhNLUtMM3BlYkxKT1ZUSUNEbmEwVzg2eEF1dTJla05GZktzX1BDZ083a0pYeHJ4TnlOOGxYUkNQR1pDRFJScVozby16eWhwblNIQWhzdU1MRHpHOGs5bHk5TFhjYXNOU1RQQ3NrZVVj?oc=5","date":"2024-11-01","type":"earnings","source":"prnewswire.com","summary":"HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update - prnewswire.com","headline":"HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxOUHM5TVJxWlBPNzBsekM2Mm5tMWhxc1VTM3ZNOTBXQ1JuQWtrTmNybTRkV0l1SkQwVjR4c0pFVEFTN3I2UFlQZXVzRHdUSG5YYk8tUWpiUzVkQlg5RVR1WGhtNTBXNGVvakNNU3piLTdBSEozQUpKaWFqanRkazA3em1wM3ZsVDZzVVlqOWE3N0lUVzh3b0JfYXMyZ1ktUk5XdTl6aXhGdHh2a09kWmNKYk50LXlLVTdQZ2hUNXRBQmlrQ3VmY1NoT2IybUhsUGNM?oc=5","date":"2024-07-26","type":"earnings","source":"prnewswire.com","summary":"HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update - prnewswire.com","headline":"HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQWGhNWkZhQXA3U095Zzh2bmlVV3lzQVJfLU1mUVlPT2lkSnM4VEI1LXJabVY4NmJydjU3M3dGeEpwMGhraUFWOXpHaUFaX1pRck5odjVuc1VlZXRIUzRoRV83dVV5dlM5MFFwYzg3Mnk1b01NangtZVJPV00xcHNCc0tDNGtOMjBDY3ZOZ1EwaUVrMjd6NUFsTFJGR2NaZk1fVm9jMWRrcXE?oc=5","date":"2024-05-28","type":"deal","source":"Longevity.Technology","summary":"Turn Bio inks $300m epigenetic reprogramming deal with HanAll Biopharma - Longevity.Technology","headline":"Turn Bio inks $300m epigenetic reprogramming deal with HanAll Biopharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxOUG5zYmJpN0EyUGR1T3JRTHdCOC12MFhmazlTZW5xQkt0c20wTGVtTGpLN19fV21hVkFNRi15X1ZvcjZEc0ZnUWE4T2JSRDQtMVJkOWJndUYtNVdycU8xWGRiYzNzQS1TbzBVaWEyUkxNc3Q1NWFIVGJXQ1UyeU00V0pJcHpJbEdac2ItMlpmNFlLY0pUMzJ4cHhSbkt2di1sZ0hXOEY5WHRlaGNPbkFRYThJa0xsRU9DVTZzYXdGS0Myc0I5X2VUbXlSN3FKcTlTcWpCaUdJQ0R0dDR1em1rb3R3aWtqal96aUg3dVFETE9VZF9YYUhPaHo0UnZSOW8xbzhWWlZPVFdnem8?oc=5","date":"2023-10-12","type":"trial","source":"prnewswire.com","summary":"HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192 - prnewswire.com","headline":"HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of H","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxPZ1BSeHVNVThwMFljUVlZVXJhT2ctcXhONkxqa0tkc3AwSjExNU1CaW1Ud1VVbGxScFdxTF84SHNuUDJkSmIwYktwX0pfR0J1RnpmZTU2Z3paeVl0ZV9kNlV5X19VYnR1MU1kS3BYMXg2MVA4bEhuT3hSLXVWLTdJbkxtandJWTVkaExPQUQ0RmZpM0p6ajdCYUM0Q05BUHI0NVM1cUd2bW1ldzA1SGtlcVIyenUzcFVsclQxc3V5RlVBV2VDS2hnZ2k5SWc3R1VjVkRUS0hyRzRiNFlYeFFJLUdLd0UxMHlYc3J6azNCTEhtUU1vd3JwdEZSTWdyS2ZwbjBkdTVtbkxycXQwZXRYWHBPc3BFOE5HZlA3OFJhOS1BUl9PUW91eW5YMEtFNFE?oc=5","date":"2023-05-25","type":"pipeline","source":"prnewswire.com","summary":"HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease - prnewswire.com","headline":"HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFBoLWo5ME5vLWFrXy1JalFFQ0xqSWJjNXppQ01CQ1VEdmNUUlhsUF9Lci0tVFBMaWZZVmN2YjV0dWtyTXVWMzVsTXMzM1d4UFp6RkdJMEdKMVk3enNLUGRaYTJ3NmFqaFVtajJhTw?oc=5","date":"2023-03-15","type":"pipeline","source":"팜뉴스","summary":"HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program - 팜뉴스","headline":"HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program - 팜뉴스","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQZUZjUU95Tk4ySlgwQXVWeFlTZnlaalBUR2NnWlFacGxZRzUyMThjMkpSdTZBNkRMbnlpY2E2cUFiTjF0NkFZemdTaDIyQ2hHMTI2UXo1UTcxa1BMbmJPY3JLcEpTT3N5OTJyQXlHbFpPRWlXUkhrWjlxa3NaeHhGcGlNX1l0TEhiUV9pV1BpS1FpYVBOYnNBTElqR01rUEROTkJNU25qOVF3UEZuUEcySjlGdlJCLXpNNE5KMC1LeVFiY2U2R0puTVdBdVJieDFkWkUwM0FLMnlaa1A5TVB3NDQyajljbjJmMnlTRmpYR1Rkc1NFWlF2MXN2UUR0SkVkMjJ5TTd3?oc=5","date":"2022-10-11","type":"deal","source":"prnewswire.com","summary":"HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab - prnewswire.com","headline":"HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":2,"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}